Summary by Moomoo AI
CANSINOBIO announced that its Diphtheria-Tetanus-Pertussis vaccine (DTcP) has entered the phase III clinical trial stage, marking significant progress in the vaccine development. The DTcP vaccine is a combination vaccine used to prevent diphtheria, tetanus, and pertussis, which is crucial for children's health. Entering phase III clinical trials indicates that the vaccine has completed preliminary safety and efficacy assessments and is about to enter large-scale human trials.According to the announcement, the phase III clinical trial for the DTcP vaccine is planned to start on December 16, 2024. The trial will involve infants aged 1 to 24 months and will be divided into 3 doses, with each dose spaced 6 months apart. This trial design aims to comprehensively assess the safety, efficacy, and immunogenicity of the vaccine in the target population. The CEO of CANSINOBIO, Xuefeng YU, and the CFO, Shou Bai CHAO, have both expressed high importance on this project and look forward to adding a new important member to the company’s vaccine product line through this clinical trial.
